Barclays has initiated coverage on Waters (WAT) with an Overweight rating and a $400 price target, following Waters’ strategic acquisition of Becton Dickinson’s Life Sciences Bioprocessing segment. This acquisition is expected to strengthen Waters’ market position in medical diagnostics and research. The company exhibits strong financial health with robust revenue growth, high operating margins, and a solid balance sheet, positioning it well for future growth despite sector-specific risks.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Waters (WAT) Gains Barclays' Favor Following Strategic Acquisiti
Barclays has initiated coverage on Waters (WAT) with an Overweight rating and a $400 price target, following Waters’ strategic acquisition of Becton Dickinson’s Life Sciences Bioprocessing segment. This acquisition is expected to strengthen Waters’ market position in medical diagnostics and research. The company exhibits strong financial health with robust revenue growth, high operating margins, and a solid balance sheet, positioning it well for future growth despite sector-specific risks.